Lancet JE, et al. - Given that, prior clinical studies have shown a sustained drug ratio and exposure in vivo and prolonged survival with CPX-351 (a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells) vs standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Researchers performed this open-label, randomized, phase III trial to assess overall survival in 309 patients age 60 to 75 years who received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen for newly diagnosed high-risk/sAML. In this patient populace, a significantly longer survival was reported in relation to CPX-351 treatment vs conventional 7+3. CPX-351 demonstrated a safety profile similar to that of conventional 7+3 therapy.